// App-Quantinova.ai

TPS785 : Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study.

Researchers

Presenter

  • David Cunningham

Principal Investigators

  • Werner Scheithauer

  • Alfredo Zurlo

  • Ramon Salazar

  • Michel Ducreux

  • Tom Samuel Waddell

  • Christophe Tournigand

  • Alberto F. Sobrero

  • Eric Van Cutsem

  • Dirk Arnold

Medical Centers

  • Royal Marsden Hospital, Surrey, United Kingdom

  • Medical University of Vienna, Vienna, Austria

  • Mologen AG, Berlin, Germany

  • ICO Institut Catala d'Oncologia, Barcelona, Spain

  • Institut Gustave-Roussy, Villejuif, France

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Oncology Department, Hopital Henri Mondor, APHP, Creteil, France

  • IRCCS San Martino - IST, Genoa, Italy

  • University Hospital Gasthuisberg, Leuven, Belgium

  • Klinik fur Tumorbiologie, Freiburg, Germany

Locations

  • United Kingdom

  • Austria

  • Germany

  • Spain

  • France

  • Italy

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • Carcinoembryonic antigen

Drug/Treatment

  • Lefitolimod

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02077868

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved